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The primary result of the Thrombolysis in
~arct~o~ ( inical trial was outcome at 6 
weeks after treatment of evolving myocardial infarction witb 
thrombolytic therapy compared between patients assigned 
to a conservative management strategy and patients assigned 
to an invasive management strategy. The conservative strat- 
egy reserved cardiac atheterization a d revascularization 
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for patients with rec~~~e~t s~o~ta~eo~s sy 
emia or ischemic responses on a ow kvel exercise test at 
c. The invasive strategy was baaed on 
mention with cardiac atheterization, a -
scularization procedures. The 
that the invasive approach 0 
added benefit n terms of survival or rccurrcnce 
dial infarction (1,2), am& it exacte 
hemorrhagic events (3). 
Some cardiovascular disease al trials have docu- 
III patients were hollowed up 
mine wketbcr there were 
purpose of this report is to comparc the results o~$c~ved at 
2- and j-year foHow-wp for the conservative and i~v~sivc 
treatment strategies in TIM11 II. 
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&&il~ of the TM II protocol have 
sewhere (t,Z). Men and women X76 years of 
mic chest pain lasting 230 min, with at least 
0 contiguous electrocardio- 
le to be treated with recom- 
activator @t-PA) (alteplase) 
within 4 h of symptom were considered for study 
entry. 
Esrch~sion criteria were agitation or lethargy such that 
informed consent could not be obtained; history ~fcwdm- 
ioplasty or severe traurntr 
~r~v~~us orou~ry artery b 
&red me.ntal st;EltusJ, or other serious illness, such as ~~n~~r 
tients were randomly ~ss~n~d to 
: either the invasive strategy 
y petformed 18 to 48 h after 
study entry, folloLWd by Coronary ao$ioplasty or coronary 
artery bps eg if the coronary anatomy was suitable 
for revascularization, r the conservative strategy 
ventional care without routine coro~~y an 
revascularization 
taneous or exerci 
indications arose., such as 
ese events were classi 
ent assignment and accordin 
the classification f these v 
For discrete variables, comparisons 
of mean values were made with two-sample t tests (13). 
t rates were estimated using the product 
ier) method (141, and comparisons in the 
e were made using the L 
d treatment strategy 
mt stm&egy and baseEne characteristics 
were evacuated using the BreaBow-Day test for homogeneity 
of odds ratios (16). These analyses were performed using 
Statistical Analysis System ( 
To adjust for multiple test 
O.Of and 0.001 for two-sided tests were specified as providing 
some vidence ofdifferences, and probability values <O.oOl 
were specified as providing strong evidence of differences. 
strategy rmp patients 
3987, 992 invasive strategy ( 
strategy (91 A%) group atients 
years after study entry an (89.6%) and 976 (90.5%) 
patients, respectively, had w-up for nntafatal events. 
The 2,174 patients enrolled before September 1987 were 
similar to the I) 165 enrolled between October 1987 and June 
1988, except Iltit the time to e~r~~~rne~t before September 
1987 was on average 2.5 the onset of pain, w 
that from October 1987 t h June 1988 was on average 
2.7 h from the onset of pam 2-min difference, p < 0.001). 
~~~~ff~~~i~~ sCra% 
le for the TIMI III trial 
csmbined end point of death or ~Q~fata~ r~ flfar~ti~~ at 6 
nt to 2 years there was no 
vasive and ~~~~e~~ative 
ence of reinfarction and 
incidence ofdeath reinfarction (Table 1, Fig. I and 2). In 
the cohort of patients enrolled before September 1987, the 
results in the 1st 2 years of follow-up were similar to those 
for patients not in this cohort, and there was no difference 
between i vasive and ccmservative strategy group atients in
se of 3 years of folBo 
course of 2 years of 
ategy growp atients was 
atients in the imvasive strate 
within 2 years of study entry, as did 
patients inthe conservative strategy group who had at least 
ported for B 16 of f lf4 patient 
and was the infarct-relate 
patients in the conservati 
related artery was instrum 
the invasive strate 
conservative strategy group. The fre~~e~~ 
ing was similar in the two groans (Table 3). 
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IMI II tlt$ore ~~pt~~~cr 
and angioplasty or bypms 
ithin 3 years of study en 
respectively, of patients in the 
invasive stmtegy group and 21A%, 20.2% and 38.3% of 
those in the conservative strategy group. 
tknt c cteristim, Of the 2,174 patierots who wer% 
enrolled in TIMI II before September 1987, the 3-year 
msrtdity rate was lower in men than in womn, in ~~ti~~t~ 
<30 ye~lrs old than tn gatients 270 years old, in 
law risk farm unf~omkle outcom@ than ia those 
risk, in ptients without than in those with diabetes and in 
ty incrmsed littte in the 2nd and 3rd years after 
m-dial 
wiu less evident at I year 
F@re 2. Two-year cumulative rates of death or myo- 
cardial infarction in the Tbrornbolysis in Myocardial 
~~f~tio~ trial, Pb~se II. Symbols as in Figure I. 
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Figure 3. Three-year cumulative rates of death in 
s I 
the Thrombolysis in Myocardial Infaxtioil trial, 
i 
a 
Phase II. Symbols as in Figure I. 10. 
0 IL.____ c-a‘s=-- 
0 26 52 78 104 130 V56 
WEEKS AFTER STUDY ENTF !’ 
hem~ynami~ instabil- 
ia or have d~um~nt~d 
n is advantageous in patients witk a pre 
Deaths were infrequent after I yaw. Chicd characteris- 
ties associated with increased early mortality included fe- 
male gender, age ~70 years, etes mellitus and a previous 
myocardial inf=tion. In TI I, hawever, the number of 
deaths observed in the 2nd rd years from study entry 
was relatively small, even in these patients. In patients at 
law risk for an unfavorable autcome, the mortality from 
study entry througk 3 years of follow-up was barely ~5%. 
The greatest mortality in TI I II occurred close to t 
of the presenting acute myoeardial i~far~ti~~ (211). Indeed, 
approximately haIf of the total mortality occurring in the 3 
years after the index infarction occurred uring the 1st 6 
weeks. 
In the Veterans Affairs Cooperative Study af Coronary 
Artery Bypass Surgery for Stable Angina (6), the average 
annual mortality for the 1st 7 years was 3.3% in patients 
I-~-PA Doss 
100 mg (n = L.654) 150 ng (n = 520) 
-_ 
No. 5% NO. 8 p Vaklc 
____1___1^___ 
0 wk t47 5.3 36 6.9 
1 Yr 129 7.8 SQ 9.6 
2 yr 152 9.2 54 IO.4 
3 yr 177 10.9 64 12.4 11.33 
- -__I_, 
Diahelest 
-,- 
Absent (II =i 1.87979) Prewai cn = 294) 
No. z- NO. 7% p Value 
6 wk 4.Y 34 11.6 
1 yr 1: 6.7 18.0 
2 Yr 147 7.8 ;; 19.8 
3 Yr 177 9.6 53 21.6 ,: O.oOoI 
AnginaS 
Absent h = 1.013) Prcscrlt hl = 1.1591 
No. % NO. % p Value 
6 wk 69 
1 Yr :: ::: 2: 
2 Y* 83 1: lo:5 
3 Yr 99 15; IL 12.2 0.09 
Prior MI 
Absent (n = 1,860) Prcsenlh = 314) 
NO. % No. % p value 
6 wk 93 5.0 30 9.6 
1 yr 133 7.2 46 14.6 
2 yr ISI 17.6 
3 Yr 177 ;:: 2 20.6 < o.OmH 
“Kaphn-Meier estimaies; p values from lo&rank tr.5 ts. IDiabetes slatus in one patient and angina sta&s in two 
patients were not recorded before presentation. R/11 = myocardial infarction; rt-PA = recombinant tissue-type 
plasminogen activator. 
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5, Tbapyem cumulative rates of death according to baseline characteristics in the Thrombolysis in Myocardiai Infarction trial, Phase 
Simoons et al, (24) reported a j-year mortality of 13% for 
269 patients treated with intracoronary streptokinase co 
pared with 21% for patients ass vefltiona~ therapy 
in the ~~terM~iver~~ty Cardiol e of the Nethcr- 
lands Trial. The mortality in p ated with streptoki- 
nase was greater in those with anterior than in those with 
inferior myocardiai infarction (15% vs. I I%) and in patients 
with a previous myocardial infarction than in tho.ie without 
(30% vs+ 9%). In the inter niversity Cardiology Ins 
the Netherlands Trial, the 
effects were also consistent 
invasive and con!+zrvative management strategies. 
IIn TIMI II, the generally favorabk long-term outcome 
(compared with that of patients assigned toeither surgical or 
medical therapy in recent studies) may be related at least in 
part to prompt treatment with a thrombolytic agent, followed 
frequency of recurrent a
observed between ~at~e~t~ 
bolytic therapy . . . should not nece 
co~ve~t~o~a~ mamagemellt . - .“--to 
managed after t~rombolytic ther a~cord~og t  aconser- 
vative strategy (with a~~ro~ria~e css to a~giograpby and 
revascularization if i dicated). Also, the ~~fre~~~~t events 
Z- and S-year follow 
yocardial infarction s 
tages for the invasive strategy are 
longer follow-up. 
TIM I1 patients assigned to a c~~~~~~at~v~ strategy of 
watchful waiting, with appropriate 
tality in TlIMJ 11 and other studies. 
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